Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT03385239
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 114 participants
- Registry
-
NCT03385239
-
- Other papers using this trial's data
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT03385239. Randomized; triple masking; primary purpose treatment. Start 2018-01-30 (actual); primary completion 2019-11-25 (actual). Results posted on 2023-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
- Condition
- Hypertriglyceridemia
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- ISIS 678354
- Intervention (Drug)
- Placebo
- Lead sponsor
- Akcea Therapeutics
- Collaborator
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct03385239- Content hash
11747eda912ee33b2cd0003dc6b10f87db2da90ac72969a4275ae6b018142bc8